If you invest in the stock market, you must know the Pfizer stock forecast & price prediction for 2025, 2026, 2027, 2028, 2029, and 2030. Here, you will get the detailed information regarding all your queries, such as its fundamentals, shareholdings, financial performance, future predictions, and more.
Pfizer Inc (PFE) Company Overview
In 1849, Charles Fizer and Charles F. Erhart founded Pfizer Inc., a leading American multinational pharmaceutical and biotechnology corporation headquartered in The Spiral, New York City. With a mission to deliver life-changing breakthroughs to patients, Pfizer focuses on developing and manufacturing medicines and vaccines in diverse therapeutic areas, including immunology, oncology, cardiology, endocrinology, and neurology.
Under the leadership of Chairman and CEO Albert Bourla, Pfizer has achieved significant milestones, most notably the development of the Pfizer-BioNTech COVID-19 vaccine, which generated $11 billion in revenue in 2023. The company’s diverse portfolio also includes well-known products such as Eliquis (a blood thinner), Prevnar (a pneumococcal vaccine), and Ibrance (a treatment for breast cancer).
The company continues to invest in research and development, with a focus on innovative areas such as gene therapy, mRNA technology, and artificial intelligence, aimed at addressing unmet medical needs and improving global health outcomes.
Fundamentals of Pfizer Inc (PFE)
- Market Cap: $1,24,261 Mln
- P/E Ratio: 15.54
- P/B Ratio: 1.41
- Industry P/E: —
- Debt to Equity: 0.72
- Book Value: 15.47
- ROE: 0.09%
- ROCE: 5.08%
- Dividend Yield: 7.49%
- 52-Week High: $31.54
- 52-Week Low: $20.92
Pfizer Stock Forecast 2025
After analyzing Pfizer’s past price trends and market performance, it is estimated that the stock could reach $27.18 by early 2025.
By the middle of the year, driven by market demand and sector performance, the price could rise to around $27.12
By the end of 2025, Pfizer’s stock price can achieve the target of $30.75.
| Month | Target Price ($) |
|---|---|
| PFE Stock Forecast January | $27.18 |
| PFE Stock Forecast February | $26.43 |
| PFE Stock Forecast March | $25.34 |
| PFE Stock Forecast April | $25.80 |
| PFE Stock Forecast May | $26.48 |
| PFE Stock Forecast June | $27.12 |
| PFE Stock Forecast July | $27.78 |
| PFE Stock Forecast August | $28.42 |
| PFE Stock Forecast September | $29.08 |
| PFE Stock Forecast October | $29.64 |
| PFE Stock Forecast November | $30.21 |
| PFE Stock Forecast December | $30.75 |
Pfizer Stock Forecast 2026
After analyzing Pfizer’s past price trends and market performance, it is estimated that the stock could reach $31.12 by early 2026.
By the middle of the year, driven by market demand and sector performance, the price could rise to around $33.85.
By the end of 2026, Pfizer’s stock price can achieve the target of $36.70.
| Year | Target Price ($) |
|---|---|
| Beginning | $31.12 |
| Middle | $33.85 |
| End | $36.70 |
Pfizer Stock Forecast 2027
After analyzing Pfizer’s past price trends and market performance, it is estimated that the stock could reach $37.24 by early 2027.
By the middle of the year, driven by market demand and sector performance, the price could rise to around $39.56.
By the end of 2027, Pfizer’s stock price can achieve the target of $42.10.
| Year | Target Price ($) |
|---|---|
| Beginning | $37.24 |
| Middle | $39.56 |
| End | $42.10 |
Pfizer Stock Forecast 2028
After analyzing Pfizer’s past price trends and market performance, it is estimated that the stock could reach $189.43 by early 2028.
By the middle of the year, driven by market demand and sector performance, the price could rise to around $202.35.
By the end of 2028, Pfizer’s stock price can achieve the target of $218.50.
| Year | Target Price ($) |
|---|---|
| Beginning | $43.38 |
| Middle | $46.52 |
| End | $49.65 |
Pfizer Stock Forecast 2029
After analyzing Pfizer’s past price trends and market performance, it is estimated that the stock could reach $50.30 by early 2029.
By the middle of the year, driven by market demand and sector performance, the price could rise to around $53.24.
By the end of 2029, Pfizer’s stock price can achieve the target of $56.18.
| Year | Target Price ($) |
|---|---|
| Beginning | $50.30 |
| Middle | $53.24 |
| End | $56.18 |
Pfizer Stock Forecast 2030
After analyzing Pfizer’s past price trends and market performance, it is estimated that the stock could reach $57.10 by early 2030.
By the middle of the year, driven by market demand and sector performance, the price could rise to around $60.42.
By the end of 2030, Pfizer’s stock price can achieve the target of $63.00.
| Year | Target Price ($) |
|---|---|
| Beginning | $57.10 |
| Middle | $60.42 |
| End | $63.00 |
Pfizer Stock Forecast & Price Prediction 2025 To 2030
| Year | Target Price ($) |
|---|---|
| 2025 | $30.75 |
| 2026 | $36.70 |
| 2027 | $42.10 |
| 2028 | $49.65 |
| 2029 | $56.18 |
| 2030 | $63.00 |
Pfizer Inc Major Holdings
- 0.06% – % of Shares Held by All Insider
- 67.60% – % of Shares Held by Institutions
- 67.63% – % of Float Held by Institutions
- 3,677 – Number of Institutions Holding Shares
Also Read: Mr Cooper Group (COOP) Stock Forecast & Price Prediction 2025 To 2030
Pfizer Inc (PFE) Income Statement
In 2024, the company saw solid financial growth, with revenue rising 6.84% to $63.63 billion. Operating expenses increased marginally by 5.58%, totaling $30.88 billion. However, the best performance came from net income, which grew 279.00% to $8.03 billion, leading to a significant improvement in net profit margin to 12.62%, an increase of 254.49%. Earnings per share (EPS) also grew 69.02% to $3.11, while EBITDA grew 24.22% to $23.32 billion. Interestingly, the effective tax rate was slightly negative at -0.35%, likely due to deferred tax adjustments or credits.
Pfizer Inc (PFE) Balance Sheet
On the balance sheet front, the company reported cash and short-term investments of $20.48 billion, a robust increase of 61.36%, indicating enhanced liquidity. Total assets decreased by 5.79% to $213.40 billion, while total liabilities decreased by 8.97% to $124.90 billion, improving the company’s leverage position. Total equity stood at $88.50 billion, and the price-to-book ratio stood at a moderate 1.41. The company also reported a return on assets of 4.64% and a return on capital of 6.37%, indicating efficient use of resources.
Pfizer Inc (PFE) Cash Flow
In terms of cash flows, the company generated cash from operations of $12.74 billion, reflecting a growth of 46.48%, while cash from investments was positive at $2.65 billion, up 108.22%, indicating profitable asset sales or investment returns. Cash from financing activities was highly negative at -$17.14 billion, a decline of 165.76%, likely due to debt repayments or share repurchases. As a result, the net change in cash was -$1.81 billion, a significant decline of 173.91%. Despite this, free cash flow remained strong at $12.78 billion, up 129.78%, underscoring the company’s strong operating base.
Pfizer Inc (PFE) Top Shareholders
- Vanguard Group Inc – 9.14%
- Blackrock Inc. – 7.97%
- State Street Corporation – 5.12%
- Charles Schwab Investment Management, Inc. – 2.74%
- Wellington Management Group, LLP – 2.47%
- Geode Capital Management, LLC – 2.13%
- NORGES BANK – 1.55%
- Massachusetts Financial Services Co. – 1.35%
- Morgan Stanley – 1.30%
- Northern Trust Corporation – 1.03%
FAQ
-
What is the price target for Pfizer Inc. (PFE) in 2025?
$30.75
-
Is Pfizer Inc. (PFE) a good investment?
Yes.
-
What will Pfizer Inc. (PFE) be worth in 2030?
The share price of Pfizer Inc. in 2030 is $63.00.
-
Is Pfizer a good stock?
Yes.
-
Is Pfizer Inc. overvalued or undervalued?
Pfizer Inc. stock is undervalued.
Disclaimer: The information in this article is for educational purposes only, and market analysts give the targets mentioned in it as suggestions. Therefore, before investing your money in any company, it is mandatory to get complete information about the company and consult your financial advisor.
I am a US-based financial analyst and market researcher with over 10 years of experience in analyzing stock trends and economic news. Specializes in forecasting price movements of major US stocks and delivering timely financial updates. I believe in making complex market data simple and actionable for everyday investors.
